Last reviewed · How we verify
TGRX-326
TGRX-326 is a small molecule that targets the SGLT2 receptor.
TGRX-326 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | TGRX-326 |
|---|---|
| Also known as | TGRX-326 QD (once a day) |
| Sponsor | Shenzhen TargetRx Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, TGRX-326 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2)
- TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE3)
- TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE1)
- TGRX-326 Pharmacokinetic Food Effect Bioavailability Study (PHASE1)
- TGRX-326 Pharmacokinetic Mass Balance (PHASE1)
- TGRX-326 Pharmacokinetic Drug Interaction (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TGRX-326 CI brief — competitive landscape report
- TGRX-326 updates RSS · CI watch RSS
- Shenzhen TargetRx Co., Ltd. portfolio CI